Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.

Autor:	Hou MM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Barrett JR; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Themistocleous Y; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Rawlinson TA; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Diouf A; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA., Martinez FJ; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France., Nielsen CM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Lias AM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., King LDW; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Edwards NJ; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Greenwood NM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Kingham L; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Poulton ID; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Khozoee B; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Goh C; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Hodgson SH; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Mac Lochlainn DJ; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Salkeld J; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Guillotte-Blisnick M; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France., Huon C; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France., Mohring F; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK., Reimer JM; Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden., Chauhan VS; International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India., Mukherjee P; Multi Vaccines Development Program (MVDP), New Delhi, India., Biswas S; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Taylor IJ; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Lawrie AM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Cho JS; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Nugent FL; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Long CA; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA., Moon RW; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK., Miura K; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA., Silk SE; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK., Chitnis CE; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France., Minassian AM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Draper SJ; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Jazyk:	angličtina
Zdroj:	Science translational medicine [Sci Transl Med] 2023 Jul 12; Vol. 15 (704), pp. eadf1782. Date of Electronic Publication: 2023 Jul 12.
DOI:	10.1126/scitranslmed.adf1782
Abstrakt:	There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu